UBA2 as a Prognostic Biomarker and Potential Therapeutic Target in Glioma. 2024

Yuhong Ou, and Hongtao Luo, and Qiuning Zhang, and Tianqi Du, and Ruifeng Liu, and Dandan Wang, and Junru Chen, and Meng Dong, and Yuhang Wang, and Zhen Yang, and Xiaohu Wang
The First School of Clinical Medicine, Lanzhou University, 730030 Lanzhou, Gansu, China.

BACKGROUND Gliomas are characterized by aggressive behavior, leading to severe disability and high mortality. Ubiquitin-like modifier activating enzyme 2 (UBA2) is a subunit of the E1-activating enzyme involved in the SUMOylation (SUMO, small ubiquitin-related modifier) of numerous proteins. Although the abnormality of UBA2 is linked to the progression of various tumor types, the role of UBA2 in glioma is still unknown. METHODS A bioinformatic analysis using several public databases was conducted to examine the expression level, clinicopathological correlations, and prognostic significance of UBA2 in glioma. The correlation between UBA2 expression and drug sensitivity in cancers was also explored. Multiple cellular experiments were conducted to validate the role of UBA2 in glioma. RESULTS Analysis of multiple databases and cellular experiments revealed that UBA2 was overexpressed in glioma tissues and cell lines, respectively. UBA2 expression in gliomas correlated with World Health Organization (WHO) grade, IDH gene status, 1p19q deletion, histological type, and immune cell infiltration in glioma. UBA2 expression in carcinomas also correlated with drug sensitivity. Kaplan-Meier analysis revealed that high expression of UBA2 predicted poorer survival in glioma patients. A nomogram model containing UBA2 expression was constructed for clinical practice. Knockdown of UBA2 was observed to suppress glioma cell progression and sensitize glioma cells to irradiation in vitro. CONCLUSIONS Overall, this research showed that UBA2 might be involved not only in the development of glioma but also in the regulation of immunity, drug sensitivity, and radiosensitivity. Therefore, UBA2 may be a potential target for therapy and a candidate biomarker for glioma diagnosis and prognosis.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011836 Radiation Tolerance The ability of some cells or tissues to survive lethal doses of IONIZING RADIATION. Tolerance depends on the species, cell type, and physical and chemical variables, including RADIATION-PROTECTIVE AGENTS and RADIATION-SENSITIZING AGENTS. Radiation Sensitivity,Radiosensitivity,Sensitivity, Radiation,Tolerance, Radiation,Radiation Sensitivities,Radiation Tolerances,Radiosensitivities,Sensitivities, Radiation,Tolerances, Radiation
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D044764 Ubiquitin-Activating Enzymes A class of enzymes that catalyzes the ATP-dependent formation of a thioester bond between itself and UBIQUITIN. It then transfers the activated ubiquitin to one of the UBIQUITIN-PROTEIN LIGASES. Ubiquitin-Activating Enzyme,Ubiquitin-Activating Enzyme E1,Ubiquitination Activating Enzyme E1,Enzyme E1, Ubiquitin-Activating,Enzyme, Ubiquitin-Activating,Enzymes, Ubiquitin-Activating,Ubiquitin Activating Enzyme,Ubiquitin Activating Enzyme E1,Ubiquitin Activating Enzymes
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Yuhong Ou, and Hongtao Luo, and Qiuning Zhang, and Tianqi Du, and Ruifeng Liu, and Dandan Wang, and Junru Chen, and Meng Dong, and Yuhang Wang, and Zhen Yang, and Xiaohu Wang
January 2023, Molecular biology reports,
Yuhong Ou, and Hongtao Luo, and Qiuning Zhang, and Tianqi Du, and Ruifeng Liu, and Dandan Wang, and Junru Chen, and Meng Dong, and Yuhang Wang, and Zhen Yang, and Xiaohu Wang
January 2024, Journal of Cancer,
Yuhong Ou, and Hongtao Luo, and Qiuning Zhang, and Tianqi Du, and Ruifeng Liu, and Dandan Wang, and Junru Chen, and Meng Dong, and Yuhang Wang, and Zhen Yang, and Xiaohu Wang
August 2021, Cancer cell international,
Yuhong Ou, and Hongtao Luo, and Qiuning Zhang, and Tianqi Du, and Ruifeng Liu, and Dandan Wang, and Junru Chen, and Meng Dong, and Yuhang Wang, and Zhen Yang, and Xiaohu Wang
January 2022, Journal of immunology research,
Yuhong Ou, and Hongtao Luo, and Qiuning Zhang, and Tianqi Du, and Ruifeng Liu, and Dandan Wang, and Junru Chen, and Meng Dong, and Yuhang Wang, and Zhen Yang, and Xiaohu Wang
July 2021, Cells,
Yuhong Ou, and Hongtao Luo, and Qiuning Zhang, and Tianqi Du, and Ruifeng Liu, and Dandan Wang, and Junru Chen, and Meng Dong, and Yuhang Wang, and Zhen Yang, and Xiaohu Wang
September 2014, Digestive diseases and sciences,
Yuhong Ou, and Hongtao Luo, and Qiuning Zhang, and Tianqi Du, and Ruifeng Liu, and Dandan Wang, and Junru Chen, and Meng Dong, and Yuhang Wang, and Zhen Yang, and Xiaohu Wang
June 2019, Cancers,
Yuhong Ou, and Hongtao Luo, and Qiuning Zhang, and Tianqi Du, and Ruifeng Liu, and Dandan Wang, and Junru Chen, and Meng Dong, and Yuhang Wang, and Zhen Yang, and Xiaohu Wang
December 2020, Journal of immunology (Baltimore, Md. : 1950),
Yuhong Ou, and Hongtao Luo, and Qiuning Zhang, and Tianqi Du, and Ruifeng Liu, and Dandan Wang, and Junru Chen, and Meng Dong, and Yuhang Wang, and Zhen Yang, and Xiaohu Wang
April 2020, Oncology reports,
Yuhong Ou, and Hongtao Luo, and Qiuning Zhang, and Tianqi Du, and Ruifeng Liu, and Dandan Wang, and Junru Chen, and Meng Dong, and Yuhang Wang, and Zhen Yang, and Xiaohu Wang
August 2021, World journal of gastrointestinal oncology,
Copied contents to your clipboard!